TL;DR
A study published in JAMA indicates that measuring apolipoprotein B (apoB) is more effective than traditional LDL cholesterol tests for guiding cholesterol-lowering treatment. This could lead to better prevention of heart attacks and strokes, but apoB testing is not yet widely used.
New research from Northwestern Medicine suggests that millions of Americans may be receiving less effective cholesterol testing, as a more accurate marker called apolipoprotein B (apoB) could better identify those at risk of heart attacks and strokes. The study, published in JAMA, found that using apoB to guide treatment decisions improves health outcomes and is cost-effective, yet it remains underused in routine care.
The study involved a computer simulation of 250,000 U.S. adults eligible for statin therapy but without existing cardiovascular disease. Researchers compared three testing strategies: LDL cholesterol, non-HDL cholesterol, and apoB, each with specific treatment goals. When patients failed to meet these goals, treatment was intensified with stronger statins and ezetimibe as needed. Over a lifetime, the apoB-guided approach resulted in fewer heart attacks and strokes and was deemed cost-effective.
Despite evidence favoring apoB, its use in clinical practice remains limited. One reason is that measuring apoB typically requires an additional blood test beyond standard lipid panels, increasing costs and inconvenience. The study’s lead author, Ciaran Kohli-Lynch, emphasized that their analysis demonstrates the value of investing in apoB testing for better risk stratification and treatment outcomes.
Why Improved Cholesterol Testing Could Save Lives
This research highlights a potential shift in how doctors assess cardiovascular risk. Using apoB could lead to more targeted treatment, preventing more heart attacks and strokes. Given the high healthcare costs associated with heart disease, adopting more accurate testing may also reduce long-term expenses and improve quality of life for many Americans.
Apolipoprotein B Test – Evaluate Your Risk of Developing a CVD – Home Testkit – CLIA Certified Laboratory Analysis – Verisana
- Assess CVD Risk: Evaluate your Apolipoprotein B levels
- Monitor Heart Health: Check Apo B for cardiovascular risk
- Home Testing Convenience: Easy at-home sample collection
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Existing Guidelines and the Need for Accurate Risk Assessment
Current guidelines primarily rely on LDL cholesterol and non-HDL cholesterol levels to determine when to start or escalate treatment. However, these tests do not fully account for the total number of harmful cholesterol particles in the blood. The emerging evidence supporting apoB suggests that it could replace or supplement existing measures, especially as new medications and guidelines encourage earlier intervention.
While the evidence is growing, apoB testing remains uncommon, partly due to additional costs and lack of awareness. The study underscores the importance of integrating this marker into routine care to enhance preventive strategies against cardiovascular disease.
“We found that apoB testing to intensify cholesterol-lowering medication would prevent more heart attacks and strokes than current practice, and that these health benefits were achieved at a cost that represents good value for U.S. healthcare payers.”
— an anonymous researcher
Remaining Questions About Widespread Adoption
It is not yet clear how quickly or widely apoB testing will be adopted in routine clinical practice. Additional research may be needed to confirm cost-effectiveness across diverse populations and healthcare settings. Moreover, insurance coverage and physician awareness could influence the pace of integration into standard care.
Next Steps for Healthcare Policy and Practice
Further efforts may focus on updating clinical guidelines to include apoB testing and on educating healthcare providers about its benefits. Policymakers and insurers will need to consider coverage and reimbursement policies to facilitate adoption. Additional real-world studies could help validate the model’s findings and support broader implementation.
Key Questions
Why is apoB considered a better marker than LDL cholesterol?
ApoB measures the total number of harmful cholesterol particles in the blood, providing a more direct assessment of cardiovascular risk than LDL cholesterol, which only measures the amount of cholesterol within those particles.
Will using apoB testing change current treatment guidelines?
While evidence is accumulating, official guideline updates are still pending. Future revisions may incorporate apoB as a preferred marker for risk assessment and treatment decisions.
Is apoB testing more expensive than standard cholesterol tests?
Yes, it generally requires an additional blood test, which can increase costs. However, the study suggests these costs may be offset by improved prevention of cardiovascular events.
When might apoB testing become routine in clinical practice?
This depends on further validation, guideline updates, and insurance coverage decisions. Adoption could accelerate over the next few years if benefits are confirmed and barriers addressed.
Does this mean current cholesterol tests are no longer useful?
Standard tests like LDL and non-HDL cholesterol still provide valuable information, but apoB may offer additional insights for more precise risk assessment and treatment planning.
Source: rss
